**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 42752

**Manuscript Type:** CASE REPORT

# Long-term survival of a patient with a large adrenal primitive neuroectodermal tumor: A case report

Dai J *et al.* Adrenal primitive neuroectodermal tumor

Jun Dai, Hong-Chao He, Xin Huang, Fu-Kang Sun, Yu Zhu, Dan-Feng Xu

**Jun Dai, Hong-Chao He, Xin Huang, Fu-Kang Sun, Yu Zhu, Dan-Feng Xu,** Department of Urology, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200025, China

**ORCID number:** Jun Dai ([0000-0002-1610-4950](http://orcid.org/0000-0002-1610-4950)); Hong-Chao He ([0000-0001-6266-4556](http://orcid.org/0000-0001-6266-4556)); Xin Huang ([0000-0002-4663-6376](http://orcid.org/0000-0002-4663-6376)); Fu-Kang Sun ([0000-0002-6950-6152](http://orcid.org/0000-0002-6950-6152)); Yu Zhu ([0000-0003-4747-4572](http://orcid.org/0000-0003-4747-4572)); Dan-Feng Xu ([0000-0002-5422-1015](http://orcid.org/0000-0002-5422-1015)).

**Author contributions:** Dai J, He HC and Sun FK provided concept of the study; Dai J and He HC searched the published articles, analyzed the data and wrote the manuscript; Huang X, Zhu Y and Xu DF collected the case history and data; Sun FK reviewed the manuscript, and confirmed the final version of this collected the funding;

**Supported by** National Natural Science Foundation of China, No. 81572621; and Medical and Technology Intercrossing Research Foundation of Shanghai Jiaotong University, No. YG2016QN65.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author to:** **Fu-Kang Sun, MD, Professor,** Department of Urology, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, No. 197, Ruijin Er Road, Shanghai 200025, China. [sunfukang6@126.com](mailto:sunfukang6@126.com)

**Telephone:** +86-21-64370045-666064

**Fax:** +86-21-64315370

**Received:** October 12, 2018

**Peer-review started:** October 13, 2018

**First decision:** October 18, 2018

**Revised:** November 11, 2018

**Accepted:** November 23, 2018

**Article in press:**

**Published online:**

**Abstract**

***BACKGROUND***

Adrenal primitive neuroectodermal tumor (PNET) is an extremely rare malignant tumor with poor prognosis and of neural crest origin. Herein, we report a case of adrenal PNET and summarized its clinical and pathological characteristics on the basis of 16 patients reported recently.

***CASE SUMMARY***

A female patient aged 25 years presented with right lumbago for 12 mo, and pre-operative CT showed a huge right adrenal mass. She received tumorectomy, and post-operative pathological examination showed adrenal PNET. After surgery, she underwent adjuvant chemotherapy and was followed up 31 mo after surgery, she received brachytherapy for right paracolic and hepatic metastases. She was alive and followed up for 56 mo. In available studies, only 57.14 % (4/7) and 44.44% (4/9) were positive for the expression of neuron-specific enolase and Synaptophysin, respectively, although CD99 expression was found in all the patients (100%; 10/10).

***CONCLUSION***

It is concluded that adrenal PNET is very rare and highly malignant, and histology is a golden standard in its diagnosis. Surgery and adjuvant therapy is the main treatment.

**Key words:** Primitive neuroectodermal tumor; Adrenal gland; Case report

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Primitive neuroectodermal tumor (PNET), a member of small round blue cell tumors, is very rare and highly malignant. PNET is usually found in the chest wall, retroperitoneal and paravertebral areas, but also reported in atypical regions. According to the location, PNET can be classified as central and peripheral PNETs. PNET originating from adrenal is extremely rare and only a few cases have been reported. Currently, the diagnosis of adrenal PNET is mostly dependent on immunohistochemistry, but its specificity is still controversial. Moreover, the outcome of adrenal PNET is poor, standard treatments have never been established so far, and the efficacy of adjuvant chemotherapy and radiotherapy after operation is still unclear. Herein, we reported a case of adrenal PNET in a female patient, and summarized the clinicopathological characteristics of adrenal PNET on the basis of 16 cases available.

# Dai J, He HC, Huang X, Sun FK, Zhu Y, Xu DF. Long-term survival of a patient with a large adrenal primitive neuroectodermal tumor: A case report. *World J Clin Cases* 2018; In press

# INTRODUCTION

Primitive neuroectodermal tumor (PNET), a member of small round blue cell tumors (SRBCT), is very rare and highly malignant. PNET is usually found in the chest wall, retroperitoneal and paravertebral areas, but also reported in atypical regions (lung, uterus, testicle, ovary and pancreas). According to the location, PNET can be classified as central and peripheral PNETs. PNET originating from adrenal is extremely rare and only a few cases have been reported[1-4]. Currently, the diagnosis of adrenal PNET is mostly dependent on immunohistochemistry, but its specificity is still controversial. Moreover, the outcome of adrenal PNET is poor, standard treatments have never been established so far, and the efficacy of adjuvant chemotherapy and radiotherapy after operation is still unclear. Herein, we reported a case of adrenal PNET in a female patient, and summarized the clinicopathological characteristics of adrenal PNET on the basis of 16 cases available.

# CASE PRESENTATION

A 25-year-old female presented with right lumbago for 12 mo without palpitation, chest distress and headache. On physical examination, palpation showed a giant mass without tenderness on the right upper abdomen; signs such as purple striae, moon face and central obesity were not observed. The patient’s blood pressure is stable (120/80 mmHg).

The renal function and metabolism of electrolytes are normal. Tumor markers such as CEA (3.14 ng/mL), AFP (1.54 ng/mL), CA125 (12.8 U/mL), CA199 (0.7 U/mL) and adrenal endocrinological examinations such as cortisol (7.56 µg/dL), aldosterone (162.7 pg/mL), metanephrine (34 pg/mL), normetanephrine (69 pg/dL) showed normal except for the elevated serum β2-microglobulin (3986 ng/mL). The abdominal ultrasonography indicated a spherical solid mass (150 mm in diameter) in the right adrenal with a clear border and a little blood flow signal. Abdominal MR revealed a huge right adrenal tumor sized 181.5 mm × 115.0 mm × 107.2 mm, with diffused intralesional hemorrhage; the right lobe of liver, right kidney and inferior vena cava were significantly compressed (Figure 1).

Surgery was performed under the general anesthesia *via* a transabdominal L-shaped incision. The hypervascular tumor was adherent to the liver and tightly connected to the right kidney and inferior vena cava. The tumor was successfully removed and the vital signs remained stable during operation. Macroscopically, the tumor was 200 mm × 160 mm in diameter and 1262 g in weight (Figure 2). The estimated intraoperative blood loss was 2000 mL. Severe complications were not observed and the patient was discharged 12 days after surgery.

**FINAL DIAGNOSIS**

Post-operative pathological evaluation revealed the tumor cells were diffusively distributed and formed Homer-Wright rosettes. Necrosis and collagen fiber hyperplasia were found (Figure 3A). The tumor cells were small and round, had little endoplasm, irregular nucleus, fine and dusty chromatin and invisible nucleolus, and a lot of cells displayed caryokinesis. Immunohistochemistry showed tumor cells were positive for CD99 (+), Vimentin (+), neuron-specific enolase (NSE) (+), Synaptophysin (SYN) (+), Bcl-2 (+), MIB-1 (10%) (+) (Figure 3B, C and D), while negative for GFAP, Nestin, MyoD1, LCA, HMB45, Melanin A, Inhibin, CHG, CD56, PGM-1, S-100, CD34 and AE1/AE3. Thus, right adrenal PNET was diagnosed on the basis of above pathological findings.

**TREATMENT**

Post-operatively, this patient received liposomal doxorubicin-based chemotherapy. Liposomal doxorubicin was administered intravenously at 60 mg once. Patients received chemotherapy for 6 courses with an interval of 2 wk between courses. Routine laboratory tests showed normal. The patient was followed up post-operatively, and recurrence and metastasis were not observed within 30 mo after surgery.

**OUTCOME AND FOLLOW-UP**

However, at 31 mo after surgery, CT and MRI revealed a right paracolic nodule (14 mm × 11 mm) (Figure 4A), and biopsy confirmed the metastasis of PNET. Then, the patient received iodine-125 brachytherapy (16965cGy). Five months later, CT showed an irregular low-density shadow in the liver (Figure 4B), and another brachytherapy (22380cGy) was administered. Currently, the patient survived after follow-up for 60 mo and the disease condition was stable.

We reviewed available 16 cases of adrenal PNET and summarized its clinicopathological features (Table 1). It seemed that the adrenal PNET had a higher incidence in Asia than in other regions (*n* = 15 in Asian *vs* 1 in the United States). Among the patients reported, female seemed to be more likely to develop adrenal PNET (12 females *vs* 4 males). The mean age of these patients was 32.6 ± 13.0 years ranging from 16 years to 57 years, and there was no evident age predisposition. More cases of adrenal PNET were found in the left adrenal, except for one bilateral adrenal PNET. Pain (flank pain, lumbodynia and abdominal pain) was the major symptom, and endocrinal examination and tumor markers detection often showed normal, except for high 24-h urine cortisol and positive low-dose dexamethasone suppression test in one case. The tumor size ranged from 3 cm to 21 cm (median: 12 cm). More than half of the patients showed adjacent organ invasion or distant metastases. Thirteen received surgical treatment, half of whom underwent further adjuvant therapy. The outcomes were poor in these patients, and the patient in our report received the longest follow-up (60 mo).

# DISCUSSION

PNET is very rare and highly malignant tumor arising from the neural crest, and belongs to the SRBCT. It was first recognized by Arthur Purdy Stout in 1918 and shares a lot of features with Ewing’s sarcoma[1-5].

PNET can be categorized into two types: Central (cPNET) and peripheral (pPNET). Both cPNETs and pPNETs are aggressive tumors, but they differ in their cell of origin. The cPNETs arise from a precursor cell of the subependymal matrix of the CNS or external granular layer of the cerebellum, pinealocytes, and subependymal cells of the ventricles whereas pPNETs derive from the neural crest located outside the CNS[6]. pPNET mainly occurs in the chest wall (also called Askin tumor), retroperitoneal and paravertebral areas and other atypical regions like lung, uterus, testicle, ovary, pancreas, bladder, parotid gland, skin and subcutaneous tissues. Among them, the adrenal PNET is extremely rare, and only a small number of cases have been reported so far[1-4].

As adrenal PNET patients usually have neither specific symptoms and signs on physical examination, nor special presentations on imaging exams and biochemical tests. Thus, most patients with adrenal PNET are in the advanced stage at the time of diagnosis[4]. The diagnosis of adrenal PNET is only dependent on pathological examination and immunohistochemistry. Microscopically, the PNET are mainly composed of small and round cells which are diffusively distributed and form several lobulated structures. The Homer–Wright rosettes or rosettes of other styles can be found[4,7,8]. Immunohistochemistry indicates that tumor cells are positive for P30/P32MIC2 (CD99), which has high specificity and sensibility in the diagnosis of PNET because CD99 expression was found in all the available patients with PNET. In addition, tumor cells may be positive for other proteins related to neural differentiation, including NSE (Uron-specific enolase), S-100 protein, Neurofilament, Syn and CgA (Chromogranin A)[4]. The genetic changes in PNET are similar to those in Ewing’s sarcoma, and both are believed to be due to a unique translocation (t (11;22)(q24q12): Fusion gene designated EWS/FLI-1)[8] (Table 2).

Pre-operative biopsy is helpful for the diagnosis of adrenal PNET. Biopsy can be performed under the guidance of an imaging system, and the transcutaneous fine-needle aspiration (FNA) is the most common method used for biopsy. As a classic method, FNA can achieve only small amount of tissues, which is not beneficial for its differential diagnosis. Furthermore, FNA also increases the risk of tumor spread (0.003%-0.009%)[6]. For the retroperitoneal PNET, endoscopic ultrasonography guided fine needle aspiration (EUS-FNA) may reduce the risk for tumor spread as compared to transcutaneous FNA[9].

Adrenal PNET is very rare, and there are no well-established guidelines or treatment strategies for PNET[10]. Surgical intervention has been accepted as a preferred treatment for adrenal PNET[3]. However, radical resection cannot be guaranteed, and recurrences and metastases are commonly reported in available reports due to the high malignancy. Generally, adjuvant chemotherapy and/or radiotherapy are administered after surgical treatment. Since PNET and Ewing’s sarcoma have the same origin, the chemotherapy with CAV (CTX + ADM + VCR) or IE (Ifosfamide, IFO + Etoposide, ETO) is recommended for the treatment of PNET[4]. According to our experience, although the sensitivity of PNET to chemotherapy is relatively low, adjuvant chemotherapy is still recommended after surgery. Of note, the efficacy of adjuvant radiotherapy is still unclear due to lack of relevant studies. Recently, it has been noted that chemotherapy might be effective only for the first few cycles, and that the tumours develop resistance very quickly[4]. In our case, the brachytherapy with iodine-125 was performed, but its effectiveness should be further confirmed in future studies. Follow-up revealed that these tumours were aggressive. Because of this high rate of recurrence, intensive follow-up with regular CT scans (every 6 mo) has been advocated even after seemingly curative surgery[11].

The reported adrenal PNET is increasing in recent years, which might be ascribed to the augmented recognition of this disease by the pathologists, especially in Asia. However, there is no epidemiological study investigating the incidence of adrenal PNET. On the basis of summary of available cases of PNET, tumor cells positive for NSE and Syn were found in only 57.14% (4/7) and 44.44% (4/9) of patients, although being positive for CD99 was noted in all the patients (10/10)[12]. It has been confirmed that CD99 (MIC2) is mainly detectable in PNETs and Ewing’s sarcoma. NSE is a neuronal marker and can differentiate PNETs from other small round cell tumors, such as Ewing’s sarcoma and neuroblastoma[1,12,13]. Thus, there might be false positive in the immunohistochemistry, and the real incidence might be lower.

Since those laboratory indicators are basically normal and there are no obvious abnormalities in the laboratory reports in other literatures, we believe that the results of laboratory examinations are not closely related to the prognosis of tumors. And there is still no indicators predicting prognosis. As for the relatively excellent outcome in our patient versus other literatures, we believe that timely chemotherapy and close follow-up after operation are essential. Furthermore, salvage brachytherapy with Iodine-125 is an effective method for small metastases detected in time. Besides, tumorectomy and the prevention of tumor damage are also essential.

In conclusion, the patient in this reported was initially treated by surgery and adjuvant chemotherapy after surgery. Salvage brachytherapy with Iodine-125 was employed when metastasis was confirmed. She was followed up for 60 mo, the longest time in available cases, and a good physical condition was observed currently in this patient. Continuous follow up is needed to assess its prognosis.

**CONCLUSION**

Adrenal PNET is very rare and highly malignant. Histology is a golden standard in diagnosis of Adrenal PNET. Surgery and adjuvant therapy is the main treatment of Adrenal PNET.

**REFERENCES**

1 **Khong PL**, Chan GC, Shek TW, Tam PK, Chan FL. Imaging of peripheral PNET: common and uncommon locations. *Clin Radiol* 2002; **57**: 272-277 [PMID: 12014872 DOI: 10.1053/crad.2001.0807]

2 **Komatsu S**, Watanabe R, Naito M, Mizusawa T, Obara K, Nishiyama T, Takahashi K. Primitive neuroectodermal tumor of the adrenal gland. *Int J Urol* 2006; **13**: 606-607 [PMID: 16771733 DOI: 10.1111/j.1442-2042.2006.01361.x]

3 **Pirani JF**, Woolums CS, Dishop MK, Herman JR. Primitive neuroectodermal tumor of the adrenal gland. *J Urol* 2000; **163**: 1855-1856 [PMID: 10799198 DOI: 10.1016/S0022-5347(05)67559-3]

4 **Zhang Y**, Li H. Primitive neuroectodermal tumors of adrenal gland. *Jpn J Clin Oncol* 2010; **40**: 800-804 [PMID: 20430773 DOI: 10.1093/jjco/hyq050]

5 **Mani S**, Dutta D, De BK. Primitive neuroectodermal tumor of the liver: a case report. *Jpn J Clin Oncol* 2010; **40**: 258-262 [PMID: 19995788 DOI: 10.1093/jjco/hyp158]

6 **Kumar V**, Singh A, Sharma V, Kumar M. Primary intracranial dural-based Ewing sarcoma/peripheral primitive neuroectodermal tumor mimicking a meningioma: A rare tumor with review of literature. *Asian J Neurosurg* 2017; **12**: 351-357 [PMID: 28761507 DOI: 10.4103/1793-5482.185060]

7 **Sofi AA**, Thekdi AD, Nawras A. EUS-FNA for the Diagnosis of Retroperitoneal Primitive Neuroectodermal Tumor. *Diagn Ther Endosc* 2011; **2011**: 198029 [PMID: 21603018 DOI: 10.1155/2011/198029]

8 **Yu ZX**, Parham DM. Paediatric soft tissue tumours: From histology to molecular diagnosis. *Diagn Histopathol* 2009; **15**: 524-530 [DOI: 10.1016/j.mpdhp.2009.08.001]

9 **Fröstad B**, Tani E, Brosjö O, Skoog L, Kogner P. Fine needle aspiration cytology in the diagnosis and management of children and adolescents with Ewing sarcoma and peripheral primitive neuroectodermal tumor. *Med Pediatr Oncol* 2002; **38**: 33-40 [PMID: 11835234 DOI: 10.1002/mpo.1260]

10 **Tsang YP**, Lang BH, Tam SC, Wong KP. Primitive neuroectodermal adrenal gland tumour. *Hong Kong Med J* 2014; **20**: 444-446 [PMID: 25307073 DOI: 10.12809/hkmj134127]

11 **Marinova L**. Retroperitoneal primitive neuroectodermal tumour (pnet). A case report and review of the literature. *Rep Pract Oncol Radiother* 2009; **14**: 221-224 [DOI: 10.1016/j.rpor.2009.11.002]

12 **Tan Y**, Zhang H, Ma GL, Xiao EH, Wang XC. Peripheral primitive neuroectodermal tumor: dynamic CT, MRI and clinicopathological characteristics--analysis of 36 cases and review of the literature. *Oncotarget* 2014; **5**: 12968-12977 [PMID: 25587032 DOI: 10.18632/oncotarget.2649]

13 **Kim MS**, Kim B, Park CS, Song SY, Lee EJ, Park NH, Kim HS, Kim SH, Cho KS. Radiologic findings of peripheral primitive neuroectodermal tumor arising in the retroperitoneum. *AJR Am J Roentgenol* 2006; **186**: 1125-1132 [PMID: 16554591 DOI: 10.2214/ajr.04.1688]

**P-Reviewer:** Cheungpasitporn W, Taheri S **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Medicine, research and experimental

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Clinical characteristic of patients with adrenal primitive neuroectodermal tumor (since 2000)**


|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case** | **Year of publication** | **Gender** | **Age (yr)** | **Side** | **Symptom (local pain)** | **Endocrinal examination and tumor marker** | **Largest diameter of tumor (cm)** | **Adjacent invasions or distant metastasis** | **Surgery** | **Adjuvant therapy** | **Outcome (mo)** |
| 1 | 2000 | M | 57 | R | - | - | 15 | + | + | N/A | N/A |
| 2 | 2002 | F | 16 | L | N/A | N/A | N/A | N/A | + | N/A | N/A |
| 3 | 2006 | F | 53 | R | N/A | - | 3 | N/A | + | - | 10 |
| 4 | 2006 | F | 25 | L | + | N/A | 15.2 | + | + | N/A | N/A |
| 5 | 2006 | F | 24 | N/A | + | N/A | 8.4 | N/A | N/A | N/A | N/A |
| 6 | 2010 | M | 30 | R | N/A | - | 12 | + | + | Radiotherapy | 8 (death) |
| 7 | 2010 | F | 21 | L | N/A | - | 10 | + | - | - | 6 (death) |
| 8 | 2010 | F | 24 | L | N/A | - | 9 | - | + | Chemotherapy | 13 (recurrence) |
| 9 | 2010 | M | 22 | L | N/A | - | 17 | + | + | Chemotherapy | Recurrence |
| 10 | 2011 | F | 17 | R | + | - | 5 | - | + | Chemotherapy + Radiotherapy | 14 |
| 11 | 2013 | F | 37 | L | + | High 24 h urine cortisol and low-dose dexamethasone test (+) | 12 | + | + | - | N/A |
| 12 | 2014 | F | 37 | L | + | - | 12 | + | + | Chemotherapy | 5 |
| 13 | 2014 | F | 40 | L |  | - | 14.6 | + | + | Chemotherapy | 8 |
| 14 | 2016 | F | 25 | R | + | - | 21 | - | + | Chemotherapy + Brachytherapy | 37 |
| 15 | 2016 | M | 45 | B | + | - | 9.6 | + | - | Chemotherapy | N/A |
| 16 | 2016 | F | 48 | L | + | - | 13 | - | + | - | 53 (recurrence) |

PNET: Primitive neuroectodermal tumor; M: Male; F: Female; R: Right; L: Left; B: Bilateral; N/A: Not applicable.


**Table 2 Pathological findings of adrenal primitive neuroectodermal tumor in available cases**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Case** | **CD99** | **NSE** | **Syn** | **CgA** | **Vimentin** | **Fil-1** | **Genetic analysis** |
| 1 | Strong+ | + | + | Faible+ | N/A | N/A | t(11:22)(q24:q12) |
| 2 | N/A | N/A | N/A N/A | N/A | N/A | N/A | N/A |
| 3 | Strong+ | + | + | N/A | - | N/A | N/A |
| 4 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 5 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 6 | ++ | - | - | - | - | N/A | N/A |
| 7 | ++ | - | - | - | + | N/A | N/A |
| 8 | + | + | - | - | + | N/A | N/A |
| 9 | + | - | (+/-) | + | - | N/A | N/A |
| 10 | + | N/A | N/A N/A | N/A | N/A | N/A | t(11:22)(q24:q12) |
| 11 | Strong+ | N/A | N/A | N/A | N/A | Faible+ | N/A |
| 12 | + | N/A | - | N/A | + | + | t(11:22)(q24:q12) |
| 13 | + | N/A | + | N/A | + | N/A | N/A |
| 14 | + | + | + | + | + | N/A | N/A |
| 15 | + | N/A | N/A N/A | N/A | N/A | N/A | N/A |
| 16 | + | N/A | N/A N/A | N/A | + | Faible+ | t(11:22)(q24:q12) |


N/A: Not applicable.




**Figure 1 Pre-operative imaging examinations.** A. Superior abdominal enhanced CT (arterial phase); B: Abdominal MRI (axial); C: Abdominal MRI (coronal). T: Tumor; L: Liver; K: Kidney; P: Pancreas; IVC: Inferior vena cava.



**Figure 2 Post-operative macroscopic examination of the tumor.** The tumor was sized 200 mm × 160 mm in diameter.



**Figure 3 Pathological changes of the tumor.** A: HE staining revealed small round tumor cells and several lobulated structures (Homer–Wright rosettes) (200 ×); B: Immunohistochemistry showed tumor cells were positive for CD99 (100 ×); C: Immunohistochemistry showed tumor cells were positive for neuron-specific enolase (100 ×); D: Immunohistochemistry showed tumor cells were positive for Synaptophysin (100 ×).



**Figure 4 CT and MRI at follow-up.** A: Abdominal MR (31 mo post-operatively) revealed a right paracolic nodule (white arrow); B: Abdominal enhanced CT showed a low-density shadow in the hepatic (black arrow).